Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search), i wt (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search), i wt (Expand Search)
-
65181
Functional effect of the Hsa-miR-185* on the <i>TrkB-T1</i> 3′UTR sequence in HEK 293 cell line.
Published 2012“…<p>A: Schematic representation of <i>TrkB-T1</i> 3′UTR sequence including the five putative binding sites for Hsa-miR-185*. …”
-
65182
-
65183
-
65184
-
65185
-
65186
-
65187
-
65188
-
65189
-
65190
-
65191
<i>apol1</i> morphant zebrafish embryos display generalized edema and glomerular filtration defects indicative of nephropathy.
Published 2015“…<p>Representative live images of (A) sham-injected control larvae, and (B) <i>apol1</i> morpholino (MO) injected larvae at 5 dpf. …”
-
65192
Rhinorrhea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65193
Vomit-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65194
Table_1_Impact of the COVID-19 Lockdown on Air Quality and Resulting Public Health Benefits in the Mexico City Metropolitan Area.DOCX
Published 2021“…SO<sub>2</sub> decreased only during Phase 3 in a near-road environment. …”
-
65195
Symptoms free-days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65196
Respiratory symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65197
Other symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65198
Diarrhea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65199
Gastrointestinal symptoms-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
-
65200
Nausea-free days up to day 10.
Published 2024“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”